Loading…
← CockpitCompetitor Analysis › NEU.AX Neuren Pharmaceuticals LimitedOpen in the cockpit ↗

Neuren Pharmaceuticals LimitedNEU.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Pharmaceuticals: Generic

NZ/Australian biotech that developed trofinetide (marketed as Daybue by US partner Acadia) for Rett syndrome and related neurodevelopmental disorders.

≈ A royalty-earning CNS biotech partnered with Acadia PharmaceuticalsMomentum leader 93
Mkt cap
$1.87B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$7.10M
20-day average traded
Fwd P/E
36.5×
forward earnings
ROIC−WACC
+5.7 pp
WACC 15.0%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · AUDA$22.11
1D-2.8%
1W-7.7%
1M+12.7%
3M-1.6%
6M+52.5%
YTD+18.8%
1Y+20.9%
ATR %4.0%
52w lowhigh9.9% off high

What Neuren Pharmaceuticals does

NZ/Australian biotech that developed trofinetide (marketed as Daybue by US partner Acadia) for Rett syndrome and related neurodevelopmental disorders.

Owns the drug but does not sell it: Acadia handles sales in North America and pays Neuren a royalty on them plus milestone payments, so income depends on Daybue sales. Neuren spends part of that cash developing its follow-on drug NNZ-2591 in other rare neurological disorders.

In one line: A royalty-earning CNS biotech partnered with Acadia Pharmaceuticals.

Products and services

  • Trofinetide (Daybue, licensed to Acadia)
  • NNZ-2591 pipeline candidate

Customers

  • Licensing partner Acadia Pharmaceuticals
  • Rett syndrome/rare disease patients (via partner)

Where it sits in the supply chain

  • Biotechnology
  • CNS/rare disease drug development
  • Licensing/royalty

What could go right

  • Royalty growth as Daybue sales scale
  • New pipeline drug approvals

What could go wrong

  • Clinical trial failure risk
  • Dependence on partner Acadia's commercialisation

Moat: narrow (IP / patents). Patent-protected drug licensed to a US commercial partner generates royalty/milestone income.

Headquarters: Auckland, New Zealand · Founded: 2003

Named competitors

Neuren Pharmaceuticals at a glance

Size Neuren Pharmaceuticals (NEU.AX) is an Australia Health Care company (Pharmaceuticals: Generic) with a market value of $1.87B, the 120th largest of 317 Australia companies the cockpit tracks. Shares closed at A$22.11 on 18 Nov 2026.

Performance Over six months the shares gained 52.5%, against -12.5% for the median peer and +1.2% for the Australia market (cap-weighted) — highest of 6 in its peer set.

Growth Revenue fell 68.0% over the last twelve months (peer median +2.5%); the operating margin is 19.9% (peer median -34.0%).

Valuation It trades at 36.5× forward earnings.

Capital Return on invested capital runs 5.7 points above its cost of capital (15.0% WACC).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026NEU.AX 153Peer median 88
Six months, rebased to 100: Neuren Pharmaceuticals against the median of its 5 peers (local-currency closes).

Neuren Pharmaceuticals financials

Reported figures in AUD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueA$69.5MA$64.6MA$213MA$232MA$14.6M
Revenue growth—-70%-8%+1,494%—
Gross profitA$69.5MA$64.6MA$213Mn/aA$14.5M
EBITDAA$13.9MA$22.0MA$176MA$199M-A$1.59M
Net incomeA$20.3MA$30.4MA$142MA$157MA$184,000
Free cash flowA$5.08MA$125M-A$11.3MA$185MA$3.58M
Capital expenditureA$40,000A$37,000A$10,000A$40,000A$19,000
Total debtn/aA$0A$0A$0A$0

Quarterly statements and history in the cockpit →

Neuren Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%26306938HIK002589301075NEU.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Neuren Pharmaceuticals is the large dot.

Neuren Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (NEU.AX vs ACAD vs AVXL vs OVID)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Neuren Pharmaceuticals NEU.AX$1.87B+52%-68%20%36.5×n/a
ACADIA Pharmaceuticals ACAD$3.08B-15%+15%10%17.8×9.2%
Anavex Life Sciences AVXLn/a-74%n/an/an/an/a
Ovid Therapeutics OVID$427M-5%-78%-4,700%n/an/a

How Neuren Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neuren Pharmaceuticals against its 5 peers (data as of 18 Nov 2026)
MeasureNEU.AXPeer medianRank in peer set
1-month return+12.7%-10.5%highest of 6
6-month return+52.5%-12.5%highest of 6
Distance from 52-week high-9.9%-43.7%2nd highest of 6
Revenue growth (TTM)-68.0%+2.5%lowest of 6
Operating margin19.9%-34.0%highest of 6
Forward P/E36.5×n/a—
ROIC minus cost of capital+5.7 pp-11.2 pphighest of 6
Net debt / EBITDA-20.6×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neuren Pharmaceuticals NEU.AXAustralia$1.87B+52%-68%20%36.5×n/an/a
Vigonvita Life Sciences 2630.HKHong Kong$1.59B-5%+763%-327%n/an/an/a
Suzhou Ribo Life Science 6938.HKHong Kong$860M-32%+4%-187%n/an/an/a
Hikma Pharmaceuticals HIK.LUnited Kingdom$4.58B+15%+2%20%9.8×2.0%+6.8%
Realcan Pharmaceutical 002589.SZChina$581M-13%-4%0%n/a16.9%-23.1%
Tibet Duo Rui Pharmaceutical 301075.SZChina$487M-51%-6%-34%n/an/an/a

Questions

Who are Neuren Pharmaceuticals's main competitors?
Named competitors: Acadia Pharmaceuticals (ACAD), Anavex Life Sciences (AVXL), Ovid Therapeutics (OVID). The cockpit's measured peer set (industry) also includes Vigonvita Life Sciences (2630.HK), Suzhou Ribo Life Science (6938.HK), Hikma Pharmaceuticals (HIK.L), Realcan Pharmaceutical (002589.SZ), Tibet Duo Rui Pharmaceutical (301075.SZ).
How has Neuren Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +52.5% against -12.5% for the median peer; over one year +20.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.